KR102515509B1 - 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 - Google Patents

결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 Download PDF

Info

Publication number
KR102515509B1
KR102515509B1 KR1020187038115A KR20187038115A KR102515509B1 KR 102515509 B1 KR102515509 B1 KR 102515509B1 KR 1020187038115 A KR1020187038115 A KR 1020187038115A KR 20187038115 A KR20187038115 A KR 20187038115A KR 102515509 B1 KR102515509 B1 KR 102515509B1
Authority
KR
South Korea
Prior art keywords
antibody
ctla
administered
nivolumab
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187038115A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015406A (ko
Inventor
마이클 액셀슨
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59078186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102515509(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Priority to KR1020237010151A priority Critical patent/KR102702675B1/ko
Publication of KR20190015406A publication Critical patent/KR20190015406A/ko
Application granted granted Critical
Publication of KR102515509B1 publication Critical patent/KR102515509B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187038115A 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 Active KR102515509B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237010151A KR102702675B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345662P 2016-06-03 2016-06-03
US62/345,662 2016-06-03
PCT/US2017/035822 WO2017210637A1 (en) 2016-06-03 2017-06-02 Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010151A Division KR102702675B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Publications (2)

Publication Number Publication Date
KR20190015406A KR20190015406A (ko) 2019-02-13
KR102515509B1 true KR102515509B1 (ko) 2023-03-28

Family

ID=59078186

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187038115A Active KR102515509B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR1020247029228A Pending KR20240134249A (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR1020237010151A Active KR102702675B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247029228A Pending KR20240134249A (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR1020237010151A Active KR102702675B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Country Status (7)

Country Link
US (3) US11332529B2 (https=)
EP (2) EP3464373B1 (https=)
JP (3) JP2019517512A (https=)
KR (3) KR102515509B1 (https=)
CN (1) CN109476754A (https=)
ES (1) ES2897964T3 (https=)
WO (1) WO2017210637A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP4098278A1 (en) 2014-11-13 2022-12-07 The Johns Hopkins University Checkpoint blockade and microsatellite instability
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3752193A4 (en) * 2018-02-13 2022-02-23 Merck Sharp & Dohme Corp. METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES
WO2020033283A1 (en) * 2018-08-09 2020-02-13 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc
AU2019337547A1 (en) * 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
CN110656179A (zh) * 2019-10-29 2020-01-07 至本医疗科技（上海）有限公司 免疫敏感性预测的生物标志组成物及用途、试剂盒设备存储介质
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
CN115569193B (zh) * 2021-10-09 2024-04-02 施慧达药业集团(吉林)有限公司 戈氏梭菌芽孢联合帕博利珠单抗的应用及治疗结肠癌药物和戈氏梭菌芽孢冻干粉制备方法
AU2023373665A1 (en) * 2022-10-31 2025-04-10 Agenus Inc. Methods of treating colorectal cancer using an anti-ctla4 antibody
WO2024167768A1 (en) * 2023-02-09 2024-08-15 Shih, Chuan Pharmaceutical kits and uses thereof for treating colorectal cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112900A1 (en) 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2015116868A2 (en) 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2016077553A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
EP1340819A1 (en) * 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
CN1845991A (zh) * 2003-08-29 2006-10-11 田中纪章 核酸扩增用引物以及利用该引物检查结肠癌的检查方法
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
FI20115709A0 (fi) * 2011-07-01 2011-07-01 Helsingin Yliopisto Menetelmä perinnöllisten syöpien diagnosointiin
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN106714836A (zh) * 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
CN110505882A (zh) * 2017-03-31 2019-11-26 默沙东公司 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112900A1 (en) 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2015116868A2 (en) 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2016077553A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability

Also Published As

Publication number Publication date
KR20240134249A (ko) 2024-09-06
JP7721494B2 (ja) 2025-08-12
CN109476754A (zh) 2019-03-15
KR20190015406A (ko) 2019-02-13
KR102702675B1 (ko) 2024-09-05
JP2025143276A (ja) 2025-10-01
US20220356254A1 (en) 2022-11-10
KR20230047498A (ko) 2023-04-07
US20250026831A1 (en) 2025-01-23
EP3464373A1 (en) 2019-04-10
WO2017210637A1 (en) 2017-12-07
JP2023002567A (ja) 2023-01-10
US11332529B2 (en) 2022-05-17
ES2897964T3 (es) 2022-03-03
EP3988570A1 (en) 2022-04-27
EP3464373B1 (en) 2021-10-27
US20190153100A1 (en) 2019-05-23
JP2019517512A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
JP7721494B2 (ja) 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用
JP7356531B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用
US20220298243A1 (en) Anti-pd-1 antibody in combination with an anti-cd30 antibody in cancer treatment
JP2019506403A (ja) がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
KR20230144099A (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
AU2020231343B2 (en) IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
KR102946586B1 (ko) Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
WO2020007368A1 (zh) 低adcc/cdc功能性单抗及其制备方法与应用
KR102634093B1 (ko) 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
CN117603360A (zh) 用于治疗癌症的多特异性抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200602

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210930

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220626

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230324

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230324

End annual number: 3

Start annual number: 1

PG1601 Publication of registration